Alto Neuroscience, Inc. (ANRO) Revenue History
Annual and quarterly revenue from 2021 to present
ANRO Revenue Over Time (2021–2025)
ANRO Revenue Growth History
0 of 1 years with positive growth- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- -100.0%
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
ANRO Revenue Analysis (2021–2025)
Current Revenue & Growth
As of June 13, 2026, Alto Neuroscience, Inc. (ANRO) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
ANRO's historical revenue data shows various trends over time. Alto Neuroscience, Inc.'s highest annual revenue of $210,000 was recorded in 2021.
Peer Comparison
Compared to Healthcare sector peers — including NRXP, INVA (+13.6% YoY), and ACAD (+9.9% YoY). Compare ANRO vs NRXP →
ANRO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 ANROCurrent | $0 | - | - | - | |
 NRXP | $1M | - | - | -1324.4% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 AXSM | $638M | +63.9% | - | -26.5% |
ANRO Historical Revenue Data (2021–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-661,000 | - | $-66,364,000 | - |
| 2024 | $0 | - | $-502,000 | - | $-68,610,000 | - |
| 2023 | $0 | - | $0 | - | $-37,809,000 | - |
| 2022 | $0 | -100.0% | $-342,000 | - | $-29,192,000 | - |
| 2021 | $210K | - | $65K | 31.0% | $-12,056,000 | -5741.0% |
What if you invested $1,000 in ANRO back in 2021?
Total return with dividends reinvested · 5+ years of data
Calculate ReturnsHow much would $100/month in ANRO be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs ANRO Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationANRO vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowANRO — Frequently Asked Questions
Quick answers to the most common questions about buying ANRO stock.
Is ANRO's revenue growth accelerating or slowing?
ANRO TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is ANRO's revenue history from 2021 to 2026?
Alto Neuroscience, Inc. (ANRO) revenue history spans 2021 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is ANRO's long-term revenue growth rate (CAGR)?
Alto Neuroscience, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for ANRO.
Why does ANRO's quarterly revenue fluctuate?
ANRO quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Alto Neuroscience, Inc.'s revenue data from 2021 to 2026 shows full historical quarterly detail on this page.
How is ANRO's revenue distributed by segment?
ANRO reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does ANRO's revenue compare to industry peers?
Alto Neuroscience, Inc. (ANRO) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.